News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Apr 16, 2024
2024
Press Release Regulatory

Elicera Therapeutics publishes the annual report for 2023

Regulatory Press Release
Read more
Mar 28, 2024
2024
Press Release Regulatory

Nomination committee proposes CMC specialist to Elicera’s board of directors

Regulatory Press Release
Read more
Mar 25, 2024
2024
Press Release Regulatory

Elicera Therapeutics announces the last day of trading in BTU and the first day of trading in warrants of series TO2

Regulatory Press Release
Read more
Mar 22, 2024
2024
Press Release Regulatory

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB

Regulatory Press Release
Read more
Mar 11, 2024
2024
Press Release Regulatory

Elicera Therapeutics announces outcome in rights issue

Regulatory Press Release
Read more
Mar 6, 2024
2024
Press Release Non-regulatory

Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies

Non-regulatory Press Release
Read more
Mar 4, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue

Non-regulatory Press Release
Read more
Feb 23, 2024
2024
Press Release Regulatory

The subscription period in Elicera Therapeutics’ rights issue of units starts today

Regulatory Press Release
Read more
Feb 21, 2024
2024
Press Release Regulatory

Elicera Therapeutics publishes prospectus in connection with rights issue of units

Regulatory Press Release
Read more
Feb 16, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024

Non-regulatory Press Release
Read more
Feb 16, 2024
2024
Press Release Non-regulatory

Elicera invites to investor meetings on February 28[th] and 29[th] 2024

Non-regulatory Press Release
Read more
Feb 13, 2024
2024
Press Release Regulatory

Elicera Therapeutics AB (publ) Year-End Report 1 January – 31 December 2023

Regulatory Press Release
Read more
Feb 9, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma

Non-regulatory Press Release
Read more
Jan 18, 2024
2024
Press Release Regulatory

NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB

Regulatory Press Release
Read more
Jan 18, 2024
2024
Press Release Regulatory

Elicera’s Board of Directors proposes a rights issue of units of approximately SEK 64 million

Regulatory Press Release
Read more
Jan 17, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics’ co-founder Magnus Essand invited to present the company's CAR T-cell projects at the world's largest cancer immunotherapy conference, CICON

Non-regulatory Press Release
Read more
Jan 9, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics participates in a collaborative project for the development of improved CAR T-cell production that has been awarded research support of SEK 850 thousand

Non-regulatory Press Release
Read more
Dec 22, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics' co-founder receives a grant totalling 4.8 MSEK from the Swedish Childhood Cancer Fund to support CAR T-cell research

Non-regulatory Press Release
Read more
Dec 22, 2023
2023
Press Release Non-regulatory

Elicera Therapeutics submits GMP validation data to the Swedish Medical Products Agency for the CARMA study to supplement the conditionally approved clinical trial application

Non-regulatory Press Release
Read more
Nov 30, 2023
2023
Press Release Regulatory

Elicera Therapeutics changes Certified Adviser and Liquidity provider to Carnegie Investment Bank AB (publ)

Regulatory Press Release
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.